Reports
Sale
Europe Hemoglobinopathies Market Size, Growth, Analysis: By Type: Thalassemia, Sickle Cell Disease, Other Hb Variants Diseases; By Treatment: Stem-Cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, Ace Inhibitors, Hydroxyurea, Others; By Test Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Europe Hemoglobinopathies Market Outlook
The global hemoglobinopathies market size was valued at USD 6.9 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of thalassemia and sickle cell anemia. The global market is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to attain USD 15.9 billion by 2032.
Key Takeaways
- Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The increasing prevalence of hemoglobinopathies in European countries is poised to directly impact the market demand for effective and affordable treatment solutions in coming years.
- One of the major Europe hemoglobinopathies market trends is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023, the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals (Ireland) Limited to treat transfusion‑dependent beta thalassemia and severe sickle cell disease.
- The market is witnessing a rise in strategic partnerships among the key market players to expand their presence in the European market. In March 2023, AddMedica and Abacus Medicine Pharma Services entered a partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) in the Western Europe region.
Europe Hemoglobinopathies Market Analysis
Hemoglobinopathies are a group of inherited blood disorders that affect the structure, function, or production of the hemoglobin molecule. The condition is usually resulted due to genetic mutations that damage or deform the red blood cells. Sickle cell anemia and thalassemia are considered the most common types of hemoglobinopathies. The disorder presents a significant health challenge in Europe. Several factors such as technological advancements in screening and diagnostic tools, rigorous research, and development efforts, and rising regulatory support are expected to drive the Europe hemoglobinopathies market growth.
The increasing prevalence of hemoglobinopathies in Europe is poised to directly impact the market demand for effective and affordable treatment solutions. Recent data reports sickle cell disease as the leading rare disease in France with around 30,000 patients affected by the condition. The rising cases of the disease stimulate innovation in screening, diagnosis, and management strategies. Moreover, the heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies is likely to bolster Europe hemoglobinopathies market demand in the forecast period.
The favorable regulatory environment in the region is expected to improve access to innovative therapies for the growing patient base as well as encourage investments from the key market players. In December 2023, the European Medicines Agency (EMA) granted approval to the first gene therapy Casgevy (exagamglogene autotemcel) developed by Ireland based Vertex Pharmaceuticals Limited to treat transfusion‑dependent beta thalassemia and severe sickle cell disease in patients aged 12 or older. The medication employs CRISPR/Cas9 gene editing technology and has the potential to reduce the burden of frequent transfusions, thereby improving the patient’s quality of life and elevating Europe hemoglobinopathies market value.
A major market trend is the rise in strategic partnerships among the key market players to share expertise and resources and subsequently expand their presence in the European market. In March 2023, AddMedica (Specialty Pharma Company in France) and Abacus Medicine Pharma Services (a pharmaceutical company in England) entered a strategic partnership to commercialize their sickle cell disease therapy Siklos (hydroxyurea) for patients aged 2 years and above. It is to be applied in three countries of western Europe, including Belgium, the Netherlands, and Luxembourg. Siklos has the potential to prevent red blood cells from taking a sickle-celled shape and reduce the risk of vaso-occlusive crises (VOCs) in the affected people. The increased emphasis on marketing and distribution of sickle cell therapies to ensure the accessibility of treatment options in the region is anticipated to augment the market share in the forecast period.
Europe Hemoglobinopathies Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Type | Thalassemia, Sickle Cell Disease, Other Hb Variants Diseases |
| Treatment | Stem-Cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, Ace Inhibitors, Hydroxyurea, Monoclonal Antibody Medication, Others |
| Test Type | Routine Red Blood Cell (RBC) Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin Solubility Test |
| End User | Hospitals and Clinics, Diagnostics Laboratories, Others |
| Country | United Kingdom, Germany, France, Italy |
Europe Hemoglobinopathies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Limited
- Merck KGaA
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Neusoft Corporation
- Emmaus UK
- Biogen
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Test Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Europe Hemoglobinopathies Market Overview
3.1 Europe Hemoglobinopathies Market Historical Value (2017-2023)
3.2 Europe Hemoglobinopathies Market Forecast Value (2024-2032)
4 Europe Hemoglobinopathies Market Landscape*
4.1 Europe Hemoglobinopathies: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Europe Hemoglobinopathies: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Treatment
5 Europe Hemoglobinopathies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Europe Hemoglobinopathies Market Segmentation (2017-2032)
6.1 Europe Hemoglobinopathies Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Thalassemia
6.1.3 Sickle Cell Disease
6.1.4 Other Hb Variants Diseases
6.2 Europe Hemoglobinopathies Market (2017-2032) by Treatment
6.2.1 Market Overview
6.2.2 Stem-Cell Transplantation
6.2.3 Blood Transfusions
6.2.4 Analgesics
6.2.5 Antibiotics
6.2.6 Ace Inhibitors
6.2.7 Hydroxyurea
6.2.8 Monoclonal Antibody Medication
6.2.9 Others
6.3 Europe Hemoglobinopathies Market (2017-2032) by Test Type
6.3.1 Market Overview
6.3.2 Routine Red Blood Cell (RBC) Count
6.3.3 Genetic Testing
6.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
6.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
6.3.6 Hemoglobin electrophoresis (Hb ELP)
6.3.7 Hemoglobin Solubility Test
6.4 Europe Hemoglobinopathies Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Diagnostics Laboratories
6.4.4 Others
6.5 Europe Hemoglobinopathies Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 United Kingdom
6.5.3 Germany
6.5.4 France
6.5.5 Italy
6.5.6 Others
7 United Kingdom Hemoglobinopathies Market (2017-2032)
7.1 United Kingdom Hemoglobinopathies Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Thalassemia
7.1.3 Sickle Cell Disease
7.1.4 Other Hb Variants Diseases
7.2 United Kingdom Hemoglobinopathies Market (2017-2032) by Treatment
7.2.1 Market Overview
7.2.2 Stem-Cell Transplantation
7.2.3 Blood Transfusions
7.2.4 Analgesics
7.2.5 Antibiotics
7.2.6 Ace Inhibitors
7.2.7 Hydroxyurea
7.2.8 Monoclonal Antibody Medication
7.2.9 Others
7.3 United Kingdom Hemoglobinopathies Market (2017-2032) by Test Type
7.3.1 Market Overview
7.3.2 Routine Red Blood Cell (RBC) Count
7.3.3 Genetic Testing
7.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
7.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
7.3.6 Hemoglobin electrophoresis (Hb ELP)
7.3.7 Hemoglobin Solubility Test
7.4 United Kingdom Hemoglobinopathies Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals and Clinics
7.4.3 Diagnostics Laboratories
7.4.4 Others
8 Germany Hemoglobinopathies Market (2017-2032)
8.1 Germany Hemoglobinopathies Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Thalassemia
8.1.3 Sickle Cell Disease
8.1.4 Other Hb Variants Diseases
8.2 Germany Hemoglobinopathies Market (2017-2032) by Treatment
8.2.1 Market Overview
8.2.2 Stem-Cell Transplantation
8.2.3 Blood Transfusions
8.2.4 Analgesics
8.2.5 Antibiotics
8.2.6 Ace Inhibitors
8.2.7 Hydroxyurea
8.2.8 Monoclonal Antibody Medication
8.2.9 Others
8.3 Germany Hemoglobinopathies Market (2017-2032) by Test Type
8.3.1 Market Overview
8.3.2 Routine Red Blood Cell (RBC) Count
8.3.3 Genetic Testing
8.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
8.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
8.3.6 Hemoglobin electrophoresis (Hb ELP)
8.3.7 Hemoglobin Solubility Test
8.4 Germany Hemoglobinopathies Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals and Clinics
8.4.3 Diagnostics Laboratories
8.4.4 Others
9 France Hemoglobinopathies Market (2017-2032)
9.1 France Hemoglobinopathies Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Thalassemia
9.1.3 Sickle Cell Disease
9.1.4 Other Hb Variants Diseases
9.2 France Hemoglobinopathies Market (2017-2032) by Treatment
9.2.1 Market Overview
9.2.2 Stem-Cell Transplantation
9.2.3 Blood Transfusions
9.2.4 Analgesics
9.2.5 Antibiotics
9.2.6 Ace Inhibitors
9.2.7 Hydroxyurea
9.2.8 Monoclonal Antibody Medication
9.2.9 Others
9.3 France Hemoglobinopathies Market (2017-2032) by Test Type
9.3.1 Market Overview
9.3.2 Routine Red Blood Cell (RBC) Count
9.3.3 Genetic Testing
9.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
9.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
9.3.6 Hemoglobin electrophoresis (Hb ELP)
9.3.7 Hemoglobin Solubility Test
9.4 France Hemoglobinopathies Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals and Clinics
9.4.3 Diagnostics Laboratories
9.4.4 Others
10 Italy Hemoglobinopathies Market (2017-2032)
10.1 Italy Hemoglobinopathies Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Thalassemia
10.1.3 Sickle Cell Disease
10.1.4 Other Hb Variants Diseases
10.2 Italy Hemoglobinopathies Market (2017-2032) by Treatment
10.2.1 Market Overview
10.2.2 Stem-Cell Transplantation
10.2.3 Blood Transfusions
10.2.4 Analgesics
10.2.5 Antibiotics
10.2.6 Ace Inhibitors
10.2.7 Hydroxyurea
10.2.8 Monoclonal Antibody Medication
10.2.9 Others
10.3 Italy Hemoglobinopathies Market (2017-2032) by Test Type
10.3.1 Market Overview
10.3.2 Routine Red Blood Cell (RBC) Count
10.3.3 Genetic Testing
10.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
10.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
10.3.6 Hemoglobin electrophoresis (Hb ELP)
10.3.7 Hemoglobin Solubility Test
10.4 Italy Hemoglobinopathies Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Hospitals and Clinics
10.4.3 Diagnostics Laboratories
10.4.4 Others
11 Regulatory Framework
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication Year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by Departments
13.7 Analysis by Recipient Organization
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.2 Bio-Rad Laboratories, Inc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Bristol-Myers Squibb Company
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Novartis AG
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Pfizer Limited
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Merck KGaA
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Alnylam Pharmaceuticals, Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Sanofi
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Neusoft Corporation
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Emmaus UK
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Biogen
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 Europe Hemoglobinopathies Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Europe hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.
The heightened patient awareness coupled with the growing advocacy efforts for improved access to care and treatments for hemoglobinopathies are fuelling the demand for the market.
One of the significant trends in the market is the surge in drug approvals of innovative treatment therapies by the health regulatory bodies. In December 2023, the European Medicines Agency (EMA) approved the first gene therapy Casgevy (exagamglogene autotemcel) developed by Vertex Pharmaceuticals Limited to treat transfusion dependent beta thalassemia and severe sickle cell disease.
Based on the type, the market is segmented into thalassemia, sickle cell disease, and other Hb variants diseases.
Treatments available in the market include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, and monoclonal antibody medication, among others.
By test type, the market is divided into Routine Red Blood Cell (RBC) Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), and Hemoglobin Solubility Test.
End users of the market are hospitals and clinics, diagnostics laboratories, among others.
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy.
The key players in the market are Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Limited, Merck KGaA, Alnylam Pharmaceuticals, Inc., Sanofi, Neusoft Corporation, Emmaus UK, and Biogen.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER